![Placeholder Image Placeholder Image](https://prod.arctic.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis
-
Media ReleaseNovartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®
-
Media ReleaseNovartis to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experience
-
Media ReleaseNovartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
-
Media ReleaseSandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
-
Media ReleaseNovartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
-
StoryToward regrowing cartilage
-
StoryThe search for new options for patients with lung cancer
-
StoryAdvancing medicine through collaboration
-
StoryNovartis and UC Berkeley take on “undruggable” proteins in new collaboration
-
StoryGuidance system lights a path for drug discovery
-
StoryDiscovery gives cystic fibrosis researchers new direction
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- › Next page